Viatris Inc., a healthcare company, develops, licenses, manufactures, markets, and distributes brand and generic drugs, complex generics, biosimilars, and active pharmaceutical ingredients (APIs) worldwide. More Details
Reasonable growth potential and fair value.
Share Price & News
How has Viatris's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: VTRS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: VTRS's weekly volatility (4%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: VTRS underperformed the US Pharmaceuticals industry which returned 17.5% over the past year.
Return vs Market: VTRS underperformed the US Market which returned 35.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Viatris's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StDo These 3 Checks Before Buying Viatris Inc. (NASDAQ:VTRS) For Its Upcoming Dividend
2 months ago | Simply Wall StEarnings Update: Viatris Inc. (NASDAQ:VTRS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
3 months ago | Simply Wall StNeed To Know: Viatris Inc. (NASDAQ:VTRS) Insiders Have Been Buying Shares
Is Viatris undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: VTRS ($14.07) is trading below our estimate of fair value ($57.59)
Significantly Below Fair Value: VTRS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: VTRS is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: VTRS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate VTRS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: VTRS is good value based on its PB Ratio (0.8x) compared to the US Pharmaceuticals industry average (2.9x).
How is Viatris forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VTRS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: VTRS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: VTRS's is expected to become profitable in the next 3 years.
Revenue vs Market: VTRS's revenue is expected to decline over the next 3 years (-0.2% per year).
High Growth Revenue: VTRS's revenue is forecast to decline over the next 3 years (-0.2% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: VTRS's Return on Equity is forecast to be high in 3 years time (23%)
How has Viatris performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VTRS is currently unprofitable.
Growing Profit Margin: VTRS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: VTRS is unprofitable, and losses have increased over the past 5 years at a rate of 54.3% per year.
Accelerating Growth: Unable to compare VTRS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VTRS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.9%).
Return on Equity
High ROE: VTRS has a negative Return on Equity (-8.07%), as it is currently unprofitable.
How is Viatris's financial position?
Financial Position Analysis
Short Term Liabilities: VTRS's short term assets ($12.3B) exceed its short term liabilities ($10.0B).
Long Term Liabilities: VTRS's short term assets ($12.3B) do not cover its long term liabilities ($27.6B).
Debt to Equity History and Analysis
Debt Level: VTRS's debt to equity ratio (113.9%) is considered high.
Reducing Debt: VTRS's debt to equity ratio has increased from 73.2% to 113.9% over the past 5 years.
Debt Coverage: VTRS's debt is not well covered by operating cash flow (7.3%).
Interest Coverage: VTRS's interest payments on its debt are not well covered by EBIT (2.7x coverage).
What is Viatris's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: VTRS's dividend (3.13%) is higher than the bottom 25% of dividend payers in the US market (1.31%).
High Dividend: VTRS's dividend (3.13%) is low compared to the top 25% of dividend payers in the US market (3.54%).
Stability and Growth of Payments
Stable Dividend: Too early to tell whether VTRS's dividend payments have been stable as they only just started paying a dividend.
Growing Dividend: Too early to tell if VTRS's dividend payments are increasing as they only just started paying a dividend.
Current Payout to Shareholders
Dividend Coverage: VTRS is paying a dividend but the company is unprofitable.
Future Payout to Shareholders
Future Dividend Coverage: VTRS's dividends in 3 years are forecast to be well covered by earnings (17.2% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Michael Goettler (53 yo)
Mr. Michael Goettler serves as Chief Executive Officer and Executive Director at Viatris Inc. Mr. Goettler is a Member of the Board of Directors of Population Services International (PSI), a global organiz...
CEO Compensation Analysis
Compensation vs Market: Michael's total compensation ($USD5.47M) is below average for companies of similar size in the US market ($USD11.17M).
Compensation vs Earnings: Insufficient data to compare Michael's compensation with company performance.
Experienced Management: VTRS's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Experienced Board: VTRS's board of directors are considered experienced (3.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: VTRS insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 133.8%.
Viatris Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Viatris Inc.
- Ticker: VTRS
- Exchange: NasdaqGS
- Founded: 1961
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$17.006b
- Shares outstanding: 1.21b
- Website: https://www.viatris.com
Number of Employees
- Viatris Inc.
- 1000 Mylan Boulevard
- United States
Viatris Inc., a healthcare company, develops, licenses, manufactures, markets, and distributes brand and generic drugs, complex generics, biosimilars, and active pharmaceutical ingredients (APIs) worldwide...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/07/31 22:50|
|End of Day Share Price||2021/07/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.